Loading...
Please wait, while we are loading the content...
Similar Documents
Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
| Content Provider | MDPI |
|---|---|
| Author | Lee, Patrick Hendifar, Andrew Osipov, Arsen Cho, May Li, Daneng Gong, Jun |
| Copyright Year | 2021 |
| Description | Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fibroblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in treatment-refractory, advanced cholangiocarcinoma. In this review, we provide an up-to-date overview of the clinical development of FGFR inhibitors in advanced cholangiocarcinoma. We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma. |
| Starting Page | 1706 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13071706 |
| Journal | Cancers |
| Issue Number | 7 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-04-03 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Pathology Cholangiocarcinoma Fibroblast Growth Factor Receptor (fgfr) Pemigatinib Infigratinib Derazantinib Debio 1347 Futibatinib Tas-120 Erdafitinib |
| Content Type | Text |
| Resource Type | Article |
